Association for Accessible Medicines

What Association for Accessible Medicines does

The Association for Accessible Medicines (AAM) is the leading US trade association representing manufacturers and distributors of finished generic pharmaceuticals and biosimilars, operating from its headquarters at 601 New Jersey Avenue NW, Suite 850, Washington, DC. Founded in 2017 through a rebranding of the Generic Pharmaceutical Association, AAM is governed by a board drawn from its 28 Regular Member companies and 6 Associate Members and is led by President and CEO John Murphy III. Its members manufacture approximately 90% of all prescriptions dispensed in the United States, produce over 61 billion doses annually across nearly 150 US facilities supporting more than 36,000 jobs, and account for only 12% of total US prescription drug spending, a disparity that is the central premise of AAM's policy advocacy.

AAM's core offering is policy advocacy and industry representation rather than technology products. The organization engages federal and state governments, the FDA, the USPTO, USTR, and international trade bodies on legislative and regulatory issues including patent reform, PBM accountability, the Inflation Reduction Act, the Medicaid generics penalty, GDUFA/BsUFA user fees, and biosimilar market access. It operates the Biosimilars Council as a wholly-owned division focused on biosimilar-specific policy, files amicus briefs in consequential cases such as Hikma v. Amarin before the Supreme Court, and produces research publications including the annual U.S. Generic & Biosimilar Medicines Savings Report co-published with the IQVIA Institute, the Hatch-Waxman Turns 40 white paper, and patient storytelling through the Voices of Access program. It also runs two flagship annual events — the Access! annual meeting and the GRx+Biosims regulatory, science, and policy conference.

AAM's business model is membership dues funded by Regular Members (finished generic and biosimilar manufacturers) and Associate Members (suppliers of goods and services), supplemented by event sponsorship and publication-related revenue. Membership categories are tiered by company type and size with annual billing, and specific dues are not publicly disclosed. The association has no technology platform, no API, no proprietary software products, and no AI capabilities; its "distribution" is the delivery of advocacy outputs, research reports, and event access to members, policymakers, healthcare stakeholders, and the public through owned digital media, social channels, press releases, and direct federal and state lobbying.

Name

Association for Accessible Medicines

Legal name

Association for Accessible Medicines

Website

https://accessiblemeds.org

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

The Association for Accessible Medicines is a US trade association that advocates for manufacturers of generic and biosimilar prescription medicines before federal and state governments. Founded in 2017 and headquartered in Washington DC, it serves 28 Regular and 6 Associate Member companies representing approximately 90% of US prescriptions dispensed.

Ownership category

akta.pro rank

Product category

Pharmaceutical Trade Association

SIC

Services-Membership Organizations (8600)

akta.pro primary industry

Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

akta.pro secondary industries

Biologics & Biosimilars Distributors (HLAIAJAH), Government Pricing & Compliance (Medicare/Medicaid/340B/AMP/Best Price) (HLAIAKAE)

Keywords

• Pharmaceutical trade association
• Generic drug advocacy
• Biosimilar policy support
• Healthcare policy advocacy
• Industry membership association

Headquarters

HQ city

Washington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Membership Dues: AAM is funded through annual membership dues paid by generic and biosimilar pharmaceutical manufacturers and suppliers. The association offers Regular Membership for manufacturers and distributors of finished generic pharmaceuticals and biosimilars, and Associate Membership for suppliers of goods and services to the industry.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels12 records

Core offering

AAM is a nonprofit trade association that represents U.S. manufacturers and distributors of generic and biosimilar prescription medicines, providing unified federal and state government advocacy, legal and policy support, industry conferences, and proprietary research such as the annual U.S. Generic & Biosimilar Medicines Savings Report. It sells tiered membership (Regular Members who are manufacturers and distributors of finished generic and biosimilar pharmaceuticals; Associate Members who are suppliers of goods and services to the industry) and operates the Biosimilars Council as a wholly owned division focused on biosimilar-specific policy.

Product overview

The Association for Accessible Medicines (AAM) is a trade association representing generic and biosimilar pharmaceutical manufacturers. Rather than a unified software product, AAM offers an integrated portfolio of advocacy services, research publications, professional events, and patient education resources. Core offerings include the Biosimilars Council division for biosimilar-specific advocacy, the annual GRx+Biosims and Access! conferences for industry education, annual savings reports in partnership with IQVIA documenting healthcare cost savings, white papers on policy issues like drug shortages and patent reform, patient storytelling initiatives (Voices of Access), and legal advocacy through amicus briefs. AAM also runs the Take With Confidence quality assurance program and the 4GRxANTED awareness campaign. The association does not offer software products, APIs, or technology platforms.

Differentiator

Problem solved

Functional benefit

Brands

• Biosimilars Council: A division of AAM dedicated to improving access to safe, quality, effective biosimilar medicines through regulatory, reimbursement, political and policy advocacy

Products and services

• Regular Membership

Quantifiable outcome

• $467 billion in savings for U.S. healthcare system in 2024
• +4 more outcomes

Named customers28 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core, supporting and minor.

• Direct ReliefcoreOthersDirect Relief is a humanitarian aid organization that receives medicine donations from the generics industry through AAM's #4GRxANTED campaign. For every video created, liked or shared with the hashtag #4GRxANTED, the generics industry donates medicines to Direct Relief, which provides medical assistance to people affected by poverty or emergencies.
• CMMB (Catholic Medical Mission Board)supportingOthersCMMB is listed as a community partner collaborating with AAM on healthcare initiatives. CMMB works to deliver health services to vulnerable populations.
• Dispensary of HopesupportingOthersDispensary of Hope is listed as a community partner providing medication access to uninsured and underinsured patients. AAM supports organizations that advance community health.
• Central Union/Mission DCminorOthersAAM staff volunteers at Central Union Mission, the oldest private social service agency in Washington, DC, annually assembling and donating health kits for residents.
• IQVIA Institute for Human Data SciencecoreStrategic or Co-development PartnerAAM partners with the IQVIA Institute annually to produce the U.S. Generic & Biosimilar Medicines Savings Report, providing authoritative data on healthcare savings from generic and biosimilar utilization.
• Biosimilars CouncilcoreStrategic or Co-development PartnerThe Biosimilars Council is a division of AAM dedicated to improving access to safe, quality, effective biosimilar medicines. Established in 2015, it focuses on education, patient access, regulatory and reimbursement environment, federal and state legislation, and legal affairs for biosimilars.

Scale indicators14 records

Recent moves6 records

Expansion highlights4 records

Regional players

• International Generic and Biosimilar Medicines Association (IGBA): IGBA is the global umbrella organization for generic and biosimilar industry associations, of which AAM is a member. It operates at the international policy level (WHO, regulatory harmonization) and serves as a peer umbrella for AAM's international trade advocacy.
• Medicines for Europe: Medicines for Europe is the European generic and biosimilar industry association based in Brussels. It is the international policy counterpart to AAM, sharing advocacy priorities on biosimilars, regulatory frameworks, and IP reform across jurisdictions.
• Generic Pharmaceutical Association of India (IPA): IPA represents India's large generic manufacturing base and works on similar regulatory and IP issues as AAM. Several of AAM's U.S.-focused members (e.g., Aurobindo, Dr. Reddy's, Lupin, Sun, Zydus) operate within IPA's broader international footprint.

Direct peers

• National Community Pharmacists Association (NCPA): NCPA represents independent community pharmacies and frequently collaborates with AAM on generic-drug reimbursement, PBM reform, and Medicaid generic penalty issues. It is a direct coalition-and-advocacy peer serving overlapping members on shared legislative priorities.
• National Pharmaceutical Council (NPC): NPC is a D.C.-based policy research organization focused on biopharmaceutical evidence, access, and value policy. It operates a comparable membership-funded advocacy and research model and competes for member attention in the same evidence/policy space that AAM's white papers address.
• Healthcare Distribution Alliance (HDA): HDA is the trade association for pharmaceutical wholesalers and distributors operating in DC. Several AAM distributor members also engage with HDA on supply chain, DSCSA, and counter-medicine issues, making HDA an adjacent peer in the same DC policy ecosystem.

Broad incumbents

• BIO (Biotechnology Innovation Organization): BIO is the largest biotech trade association in the U.S., representing developers of innovator biologics. It overlaps with AAM's Biosimilars Council on biosimilar regulatory and reimbursement policy and frequently partners on FDA user-fee reauthorization cycles (BsUFA/PDUFA).
• National Association of Chain Drug Stores (NACDS): NACDS represents retail pharmacy chains and advocates on PBM reform, drug pricing, and pharmacy benefit issues. It is a coalition partner with AAM on PBM-related advocacy and shares overlapping policy concerns.
• PhRMA (Pharmaceutical Research and Manufacturers of America): PhRMA is the leading trade association for brand/innovator pharmaceutical manufacturers in Washington, DC. It is the principal counterpart to AAM in policy debates over drug pricing, patent reform, and IRA implementation, and directly competes with AAM for legislative influence and media narrative.

Others

• American Pharmacists Association (APhA): APhA is the largest U.S. pharmacy professional association and a complementary stakeholder on drug access and affordability policy. It intersects AAM's agenda on issues like drug shortages, PBM reform, and patient access to generics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/accessiblemeds
• YouTubeyoutube.com/channel/UCX1h-YqFGCGGldb48sWYAtg
• Facebookfacebook.com/accessiblemeds
• LinkedInlinkedin.com/company/11041580
• Instagraminstagram.com/accessiblemeds

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Association for Accessible Medicines